At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
ARRY-371797, p38 inhibitor, oraldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Rollover Study of ARRY-371797 in Patients With Symptomatic Genetic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation
In Brief
A Phase 2 clinical trial evaluating ARRY-371797, p38 inhibitor, oral for LMNA-Related Dilated Cardiomyopathy. Completed, enrolled 8 participants across 4 sites.
Detailed Summary
This is a rollover study designed to investigate the safety and effectiveness of investigational study drug ARRY-371797 in patients who previously received ARRY-371797 in a study for patients with LMNA-related dilated cardiomyopathy sponsored by Array BioPharma and may, in the Investigator's opinion, derive benefit from continued treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLMNA-Related Dilated Cardiomyopathy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartFeb 2015
Primary CompletionDec 2020
TodayJul 2026
First PostedJan 30, 2015
Enrollment StartFeb 2, 2015
Primary CompletionDec 21, 2020
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 11.4 years ago
Interventions
ARRY-371797, p38 inhibitor, oraldrug
multiple dose, single schedule